Treatment strategies in elderly patients with aggressive histology lymphoma

Ann Hematol. 2001:80 Suppl 3:B86-8. doi: 10.1007/pl00022799.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Age Factors
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Comorbidity
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Neutropenia / chemically induced
  • Neutropenia / prevention & control
  • Prednisone / administration & dosage
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Rituximab
  • Survival Rate
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Granulocyte Colony-Stimulating Factor
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol